Javascript must be enabled to continue!
Early signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis
View through CrossRef
The objective of the study – identify early preclinical signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis.Material and methods. We examined 142 people with verified rheumatic diseases. All patients were divided into 2 groups. The first group consisted of patients with rheumatoid arthritis – 95 people. The second group – patients with ankylosing spondylitis – 47 people. The control group included 70 practically healthy individuals. In addition to standard diagnostic tests, all patients underwent tissue dopplerography of the heart using the GE Vivid E9 ultrasound device using the two-dimensional deformation technique (speckle tracking) to assess the deformation and rate of myocardial deformation, as well as determining the level of matrix metalloproteinase-9 in the blood serum.Results. Among patients with rheumatoid arthritis, diastolic dysfunction of both the left ventricle and both ventricles was more common than in the control group. The same pattern was observed in the group with ankylosing spondylitis. The calculation of the relative risk showed that the presence of rheumatoid arthritis in 4,42 times increases the risk of diastolic dysfunction of the left ventricle in comparison with practically healthy people (CI 1,6–12,2). In individuals with rheumatoid arthritis also results in a deterioration of systolic function of both ventricles. The level of matrix metalloproteinase metalloproteinase-9 was highest and most often increased in patients with ankylosing spondylitis. Among patients with rheumatoid arthritis, the average level of metalloproteinase-9 was low, but the incidence was higher than in the control group. The obtained results indicate that in these rheumatic diseases there is a marked degradation of the extracellular matrix components.Conclusion. Patients with rheumatoid arthritis and ankylosing spondylitis are characterized by a deterioration in the diastolic function of the left ventricle or both ventricles simultaneously, which is accompanied by an increase in the level of metalloproteinase-9.
Title: Early signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis
Description:
The objective of the study – identify early preclinical signs of myocardial dysfunction in patients with rheumatoid arthritis and ankylosing spondylitis.
Material and methods.
We examined 142 people with verified rheumatic diseases.
All patients were divided into 2 groups.
The first group consisted of patients with rheumatoid arthritis – 95 people.
The second group – patients with ankylosing spondylitis – 47 people.
The control group included 70 practically healthy individuals.
In addition to standard diagnostic tests, all patients underwent tissue dopplerography of the heart using the GE Vivid E9 ultrasound device using the two-dimensional deformation technique (speckle tracking) to assess the deformation and rate of myocardial deformation, as well as determining the level of matrix metalloproteinase-9 in the blood serum.
Results.
Among patients with rheumatoid arthritis, diastolic dysfunction of both the left ventricle and both ventricles was more common than in the control group.
The same pattern was observed in the group with ankylosing spondylitis.
The calculation of the relative risk showed that the presence of rheumatoid arthritis in 4,42 times increases the risk of diastolic dysfunction of the left ventricle in comparison with practically healthy people (CI 1,6–12,2).
In individuals with rheumatoid arthritis also results in a deterioration of systolic function of both ventricles.
The level of matrix metalloproteinase metalloproteinase-9 was highest and most often increased in patients with ankylosing spondylitis.
Among patients with rheumatoid arthritis, the average level of metalloproteinase-9 was low, but the incidence was higher than in the control group.
The obtained results indicate that in these rheumatic diseases there is a marked degradation of the extracellular matrix components.
Conclusion.
Patients with rheumatoid arthritis and ankylosing spondylitis are characterized by a deterioration in the diastolic function of the left ventricle or both ventricles simultaneously, which is accompanied by an increase in the level of metalloproteinase-9.
Related Results
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
THE AUSTRALIAN RHEUMATOLOGY ASSOCIATION
The followina are abstracts of papers presented at the 35th Annual Scientific Meeting of the Australian Rheumatology Association, held in Perth, Western Australia, 1–4 December. 19...
AYURVEDIC MANAGEMENT OF ANKYLOSING SPONDYLITIS – A CASE REPORT
AYURVEDIC MANAGEMENT OF ANKYLOSING SPONDYLITIS – A CASE REPORT
Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects primarily sacroiliac joints and the spine. It is a gradually progressive condition over severa...
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
THE COMBINED AUSTRALIAN AND NEW ZEALAND RHEUMATOLOGY ASSOCIATIONS
CYTOKINES IN SLE: LESSONS FROM EXPERIMENTAL MODELS AND MAN, Michael J Elliott*., Peter Charles, Ravinder N MainiTHE FAS GENE IN HUMAN LUPUS: THE EXPRESSION OF VARIANT TRANSCRIPTS.,...
Reproductive health in women with ankylosing spondylitis: contraception and fertility. A narrative review
Reproductive health in women with ankylosing spondylitis: contraception and fertility. A narrative review
Objective. The knowledge of ankylosing spondylitis is rising, and more and more attention is being paid to the diagnosis of this pathology in females. The purpose of this narrative...
From joint to heart: Cardiovascular implications of rheumatoid arthritis
From joint to heart: Cardiovascular implications of rheumatoid arthritis
Rheumatoid arthritis is a commonly encountered autoimmune disease and a progressive chronic inflammatory condition that often leads to permanent joint damage. Systemic inflammation...
Safety and Clinical Response in Ankylosing Spondylitis after Three Months of Etanercept Therapy
Safety and Clinical Response in Ankylosing Spondylitis after Three Months of Etanercept Therapy
Abstract
Objective: To look for safety and clinical response in ankylosing spondylitis after three months of Etanercept therapy and factors associated with response.
Study Design: ...
Alteration of Bone Turnover Markers in Canonical Wingless Pathway in Patients With Ankylosing Spondylitis
Alteration of Bone Turnover Markers in Canonical Wingless Pathway in Patients With Ankylosing Spondylitis
Objectives: This study aims to determine the levels of bone turnover markers in canonical wingless pathway in patients with ankylosing spondylitis (AS) and the correlation with dis...
Co-existing Ankylosing Spondylitis and Rheumatoid Arthritis in a Patient Undergoing Total Knee Arthroplasty Under Peripheral Nerve Blocks
Co-existing Ankylosing Spondylitis and Rheumatoid Arthritis in a Patient Undergoing Total Knee Arthroplasty Under Peripheral Nerve Blocks
Introduction: While laboratory tests and clinical criteria are well-defined, the simultaneous presence of concomitant symptoms can lead to a misdiagnosis and delay in the initiatio...


